EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate

Stanislas Faguer iD, Chloé Medrano, Suzanne Tavitian, Lucie Oberic

Kidney360 · 2025-03 · 6 (3) · 476-481

DOI: 10.34067/kid.0000000725 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney360, online erschienen am 31.01.2025. Verfasst von Stanislas Faguer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Organ Transplantation, French Intensive Care Renal Network (F.I.R.N), University Hospital of Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Methotrexate, Acute Kidney Injury, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AKI is a rare but life-threatening complication of the administration of methotrexate (MTX) at high doses (≥1 g/m 2 ) for the treatment of solid or hematological malignancies. MTX overexposure can lead to MTX-AKI and subsequent higher risk of extrakidney toxicities, morbidity, and mortality. MTX-AKI can also lead to secondary CKD requiring a reduced dose or contraindication for subsequent MTX infusions, thus worsening the cancer-related prognosis. Treatment of MTX-AKI is mainly preventive, combining alkaline hyperhydration, withdrawal of all nephrotoxic agents and drugs that modulate the metabolism of MTX, metabolic salvage using leucovorin (folinic acid), and close monitoring of serum MTX and creatinine concentrations. Glucarpidase (carboxypeptidase-G2), a recombinant bacterial enzyme that hydrolyzes MTX into two noncytotoxic metabolites, should be considered for patients with MTX overexposure to prevent and lessen AKI and other potential toxicities. This article provides a comprehensive review of MTX metabolism, mechanisms and prevention of MTX-AKI, and its management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateAcute Kidney InjuryAntimetabolites, AntineoplasticHumansgamma-Glutamyl HydrolaseLeucovorinRecombinant Proteins

Substanzen

Methotrexategamma-Glutamyl HydrolaseAntimetabolites, AntineoplasticglucarpidaseLeucovorinRecombinant Proteins

Autor:innen und Institutionen

  • Department of Nephrology and Organ Transplantation, French Intensive Care Renal Network (F.I.R.N), University Hospital of Toulouse, Toulouse, France.
  • Faculty of Health, University of Toulouse-3, Toulouse, France.
  • Renal Fibrosis Lab, INSERM UMR1297, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.
  • Department of Hematology, Oncopole - Cancer Institute of Toulouse, University Hospital of Toulouse, Toulouse, France.

ORCID-Profile: Stanislas Faguer

Zitieren

APA

Faguer, S., Medrano, C., Tavitian, S., & Oberic, L. (2025). Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate. Kidney360, 6(3), 476-481. https://doi.org/10.34067/kid.0000000725

Vancouver

Faguer S, Medrano C, Tavitian S, Oberic L. Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate. Kidney360. 2025;6(3):476-481. doi:10.34067/kid.0000000725

BibTeX
@article{Faguer2025,
  author = {Faguer, Stanislas and Medrano, Chloé and Tavitian, Suzanne and Oberic, Lucie},
  title = {Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate},
  journal = {Kidney360},
  year = {2025},
  volume = {6},
  number = {3},
  pages = {476--481},
  doi = {10.34067/kid.0000000725}
}
Kostenlos starten →